TAGS: Sustainability / Natural Cosmetics Skin Care
Sytheon announces its new turnkey product for treating Atopic Dermatitis (eczema) has further patent protection – and is actively seeking an exclusive partner to bring it to the OTC dermatological market.
Sustainable, Safe, and Cost-effective Product
There is currently an unmet need for a sustainable, safe, and cost-effective product for those with mild to moderate Atopic Dermatitis (AD). Sytheon has a turnkey product, ActSES®, with solid science, patent protection, and clinical validation by UC-Davis, CA dermatologists – and a new clinical study on children underway.
Topical therapies are a mainstay treatment for AD, particularly for children or those with mild-to-moderate disease who may not qualify for systemic medications. The complexity of chronic AD is increased by the interplay of skin barrier dysfunction and immune dysregulation, resulting in the perpetuation of AD signs and symptoms.
ActSES®, a unique synergistic combination product of Isosorbide di-(linoleate/oleate) (Hydra Synol® IDL) + Isosorbide di-caprylate (Hydra Synol® DOI), has been developed by Sytheon to serve this unmet need. The effects of topically applied ActSES® are not limited to barrier repair but synergistically inhibit inflammatory cascades that amplify pruritus and cutaneous eruption.
For ActSES®, Sytheon has obtained two new US patents 11,753,414 (method) & 11,753,415 (composition), entitled “Composition and Methods for Treating Atopic Dermatitis.” Sytheon has two earlier US Patents (10,597,402 & 11,312,725), which disclose “compositions and methods for restoring epidermal integrity and function and treating dermatological diseases.”
Sytheon is actively looking for an exclusive partnership with the right organization to bring this turnkey product to the OTC dermatological market.
Explore Skin Care Range from Sytheon
Source: Sytheon
